期刊文献+

消癌平联合5-氟尿嘧啶对Hepa1-6肝癌细胞化疗增效中的作用 被引量:5

The role in the chemotherapy efficiency of Hepa1-6 cell induced by Xiaoaiping and 5-fluorouracil
下载PDF
导出
摘要 目的观察消癌平对化疗药物5-氟尿嘧啶(5-Fu)的最佳增效时间和最佳增效浓度,并探讨其发挥化疗增效作用的机制。方法采用噻唑蓝(MTT)比色法观察不同浓度消癌平联合5-Fu对Hepa1-6肝癌细胞的生长抑制作用,消癌平作用浓度分别设10、305、0 mg/mL,作用时间分别设5-Fu作用前0、8、16、24 h和作用后8、16、24 h,采用细胞划痕愈合实验测定细胞扩散运动能力。结果不同浓度消癌平联合5-Fu化疗组细胞生长抑制率均明显高于5-Fu单药组(P均<0.05),且消癌平的增效作用随其剂量的增加而增加(P<0.05),50mg/mL消癌平于5-Fu作用前8 h加入增效作用最佳(P<0.01),消癌平8 h-5-Fu给药组较肝癌细胞组、5-Fu单药组能显著减弱细胞移行运动能力。结论消癌平以50 mg/mL的浓度于5-Fu作用前8 h加入化疗增效作用最佳,消癌平主要通过减弱细胞移行运动能力发挥增加5-Fu的化疗作用。 Objective To observe the best enhancement time and concentration of Xiaoaiping on chemotherapeutic response of 5-fluorouracil(5-Fu) and to explore the mechanism of chemosensitization.Methods MTT method was used to test the growth inhibitory rate of hepatocellular carcinoma cell Hepa1-6 acted by Xiaoaiping and5-Fu.TheconcentrationofXiaoaiping was 0,30,50 mg/mL and the time point was 0,8,16,24 h before 5-Fu,and 8,16,24 h after 5-Fu.Monolayer wound healing assay was used to detect Hepa1-6 cell motility.Results The inhibitory rate of cell growth in Xiaoaiping combination groups was significantly higher than that in 5-Fu alone group(P0.05),and the enhancement increased with Xiaoaiping dosage augmented.50 mg/mL Xiaoaiing could exert the best enhancement on chemotherapeutic response of 5-Fu when it was added 8 h before 5-Fu(P0.01).Xiaoaiping 8 h 5-Fu group can weaken the cell migration ability significantly compared with hepatocellular carcinoma group and 5-Fu alone group.Conclusion Xiaoaiping could exert the best enhancement with 50 mg/mL when added 8 h before 5-Fu.
出处 《山西医药杂志(上半月)》 CAS 2011年第4期341-343,共3页 Shanxi Medical Journal
关键词 肝细胞 消癌平 氟尿嘧啶 肿瘤治疗方案 Carcinoma hepatocellular Xiaoaiping Fluorouracil Antineoplastic protocols
  • 相关文献

参考文献13

二级参考文献56

共引文献75

同被引文献50

  • 1秦叔逵,曹梦苒,钱军,华海清,王琳,何泽明.奥沙利铂为主的FOLFOX方案治疗晚期原发性肝癌[J].临床肿瘤学杂志,2005,10(1):58-60. 被引量:77
  • 2Attia S,Holen KD,Thomas JP,et al.Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular caricinoma.Clin Adv Hematol Oncol,2008,6:44-54. 被引量:1
  • 3Farinati F,Sergio A,Baldan A,et al.Octreotide and hepatocellular carcinoma.Br J Cancer,2007,96:1778-1779. 被引量:1
  • 4Reisine T,Bell GI.Molecular properties of somatostatin receptors.Neuroscience,1995,67(4):777-790. 被引量:1
  • 5Kouroumalis E,Skordilis P,Thermos K,et al.Treatment of repatocellular carcinoma with octreotide:a randomized controlled study.Gut,1998,42(3):442-444. 被引量:1
  • 6Mizukoshi E,Nakamoto Y,Marukawa,et al.Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.Hepatology,2006,43(6):1284-1287. 被引量:1
  • 7Llovet JM,Burroughs A,Bruix J. Hepatocellular carcinoma[J].The Lancet,2003,(9399):1907-1917.doi:10.1016/S0140-6736(03)14964-1. 被引量:1
  • 8Schwartz M,Roayaie S,Konstadoulakis M. Strategies for the management of hepatocellular carcinoma[J].Nat Clin Pract Oneol,2007,(07):424-432. 被引量:1
  • 9Llovet JM,Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolizafion improves survival[J].Hepatology,2003,(02):429-442.doi:10.1053/jhep.2003.50047. 被引量:1
  • 10Tashiro T,Kawada Y,Sakurai Y. Antitumora activity of a new platinum complex,oxalato (tran-I-1,2-diaminocyclohexane) platinum (Ⅱ):new experimental data[J].Biomedicine and Pharmacotherapy,1989,(04):251-260. 被引量:1

引证文献5

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部